Motley Fool Asset Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Motley Fool Asset Management LLC

$1.85 Billion
Q4 2024

A detailed history of Motley Fool Asset Management LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Motley Fool Asset Management LLC holds 48,448 shares of RARE stock, worth $1.91 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

48,448

Previous 141,649 65.8%

Holding current value

$1.91 Million

Previous $7.87 Million 74.1%

% of portfolio

0.11%

Previous 0.47%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$42.07 - $57.72 $3.92 Million - $5.38 Million	-93,201 Reduced 65.8%	48,448 $2.04 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $14,475 - $21,369	360 Added 0.25%	141,649 $7.87 Million
Q2 2024 Aug 08, 2024	SELL	$37.42 - $51.61 $195,968 - $270,281	-5,237 Reduced 3.57%	141,289 $5.81 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $69,090 - $86,226	1,606 Added 1.11%	146,526 $6.84 Million
Q1 2024 May 08, 2024	SELL	$43.02 - $53.69 $194,579 - $242,839	-4,523 Reduced 3.03%	144,920 $6.77 Million
Q4 2023 Feb 02, 2024	SELL	$31.73 - $49.19 $211,353 - $327,654	-6,661 Reduced 4.27%	149,443 $7.15 Million
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $2.25 Million - $3.01 Million	64,416 Added 70.26%	156,104 $5.57 Million
Q2 2023 Aug 09, 2023	BUY	$37.35 - $52.15 $2.13 Million - $2.98 Million	57,097 Added 165.06%	91,688 $4.23 Million
Q1 2023 May 10, 2023	SELL	$36.99 - $48.71 $87,740 - $115,540	-2,372 Reduced 6.42%	34,591 $1.39 Million
Q4 2022 Feb 09, 2023	SELL	$33.72 - $46.33 $106,251 - $145,985	-3,151 Reduced 7.86%	36,963 $1.71 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $1.68 Million - $2.78 Million	-42,092 Reduced 51.2%	40,114 $1.66 Million
Q2 2022 Aug 11, 2022	SELL	$45.8 - $85.4 $257,899 - $480,887	-5,631 Reduced 6.41%	82,206 $5.25 Million
Q1 2022 May 04, 2022	SELL	$62.2 - $84.4 $2 Million - $2.71 Million	-32,156 Reduced 26.8%	87,837 $6.38 Million
Q4 2021 Feb 10, 2022	SELL	$73.71 - $87.86 $1.06 Million - $1.26 Million	-14,364 Reduced 10.69%	119,993 $10.1 Million
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $2.85 Million - $3.75 Million	-36,639 Reduced 21.43%	134,357 $12.1 Million
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $1.72 Million - $2.16 Million	18,670 Added 12.26%	170,996 $16.3 Million
Q1 2021 May 11, 2021	BUY	$106.9 - $167.73 $10.4 Million - $16.3 Million	96,990 Added 175.27%	152,326 $17.3 Million
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $843,156 - $1.77 Million	9,990 Added 22.03%	55,336 $7.66 Million
Q3 2020 Nov 12, 2020	BUY	$72.98 - $90.0 $218,721 - $269,730	2,997 Added 7.08%	45,346 $3.89 Million
Q2 2020 Aug 12, 2020	BUY	$46.91 - $78.22 $637,225 - $1.06 Million	13,584 Added 47.22%	42,349 $3.31 Million
Q1 2020 May 13, 2020	BUY	$33.8 - $62.9 $972,256 - $1.81 Million	28,765 New	28,765 $1.28 Million

Others Institutions Holding RARE

# of Institutions

345

Shares Held

86.7M

Call Options Held

675K

Put Options Held

846K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.76B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Motley Fool Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Motley Fool Asset Management LLC with notifications on news.

Account

Motley Fool Asset Management LLC Ultragenyx Pharmaceutical Inc. Transaction History